Daniel B. Soland - Jan 24, 2022 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC. (IDRA)

Role: CHIEF OPERATING OFFICER
Signature: /s/ Daniel B. Soland
Stock symbol: IDRA
Transactions as of: Jan 24, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/26/2022, 07:42 PM
Previous filing: Oct 1, 2021
Next filing: Apr 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IDRA	Stock Option (Right to Buy)	Award	$0	+25K		$0.00	25K	Jan 24, 2022	Common Stock	25K	$0.57	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 24, 2022. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 24, 2023 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Content

The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 24, 2022. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 24, 2023 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.